Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (604)	5/3/2001 2:42:41 AM
From: tuck	Read Replies (1) \| Respond to of 1784

Wilder, Muchas gracias for the notes. I think MDZ is a buy ~$13. Trickle would buy more, but figures 200 shares is enough for now. Dang dividends; makes a portfolio manager's life more complicated. Gotta finish that new line item in the portfolio, but it's a low priority right now. Hey, Rick, you've got MDZ. How are you dealing with dividends in the portfolio interface? I made mine a WatchList item (cumulative $ total given, but no shares) and added to cash. Seems to work, but it needs updating. Meanwhile, PCOP, which looked like it was getting some earnings momentum going, loses it. Given the wide range of the estimates, I guess they didn't feel obligated to warn earlier. Reckon Trickle's %loss will pop back over 20 tomorrow, darn it. >>Pharmacopeia posts Q1 loss, cuts full-year EPS view PRINCETON, N.J., May 2 (Reuters) - Pharmacopeia Inc. (NASDAQ:PCOP), which helps develop and test new drugs and chemicals, on Wednesday posted a first-quarter loss and lowered its earnings per share outlook for the year. The company said its pro forma net loss excluding charges totaled $2.3 million, or 10 cents per diluted share, compared with pro forma earnings of $1.1 million or 5 cents per share a year earlier. Four analysts polled by Thomson Financial/First Call had expected the company's first-quarter results to range from a loss of 17 cents per share to a profit of 9 cents per share, with a mean of a profit of 1 cent. Pharmacopeia said its net loss, including acquisition-related charges, was $5.8 million, or 25 cents per share. Revenue in the first quarter totaled $27.1 million, up from $23.9 million a year earlier. Citing a "slow start" in the company's drug discovery business in the first quarter, Chairman, President and Chief Executive Joseph Mollica said Pharmacopeia now expects full-year pro forma earnings per share of 70 cents, from 80 cents previously.<< snip Cheers, Tuck